Elanco and Aratana Therapeutics finalize deal to mergeJuly 18, 2019Elanco Animal Health has acquired Aratana Therapeutics. Structured as a stock-for-stock transaction, the deal was accepted by Aratana stockholders. “Aratana’s strong position in the specialty market—with its current portfolio and pipeline—complements Elanco’s field presence and capitalizes on new opportunities for key existing Elanco pet therapy brands,” says Jeff Simmons, president and chief executive officer of Elanco. “This deal furthers Elanco’s value-generating innovation, portfolio, and productivity (IPP) strategy, while continuing to bring great value to veterinarians …
SPONSORED CONTENTFeline urinary health—meet a simple solutionUrinary health is complicated, but the solution doesn’t have to be. Our products nutritionally support urinary tract and bladder health at any stage. + Recommend Today
Aratana Therapeutics’ Nocita 10 ml gets FDA approvalJune 13, 2019Aratana Therapeutics announced the U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM) has approved an additional vial size (10 ml) of Nocita. “Since its launch in 2016, Nocita has drastically changed veterinary multimodal pain management protocols because it safely and effectively controls pain in patients for up to 72 hours following certain canine and feline surgeries,” says Aratana Therapeutics chief development officer, Ernst Heinen, DVM, PhD. “Ultimately, we believe a smaller …
Elanco Animal Health to acquire Aratana TherapeuticsApril 30, 2019Elanco Animal Health has signed an agreement to acquire Aratana Therapeutics. The deal allows Elanco to integrate the Aratana portfolio of pet therapeutics into its companion animal therapeutics business. “Aratana has been one of the most innovative start-ups in animal health, bringing breakthrough solutions to the market,” says Elanco president and chief executive officer, Jeff Simmons. “We look forward to putting greater energy behind these brands with our increased share of voice in the …
Aratana Therapeutics seeks feline label expansion for NocitaJune 12, 2018Aratana Therapeutics Inc. announced it has submitted a supplemental new animal drug application with the FDA to approve the use of Nocita in cats to provide regional analgesia following onychectomy. Nocita (bupivacaine liposome injectable suspension), which provides up to 72 hours of analgesia postoperatively using multivesicular liposomal technology, was first approved in August 2016 for canine use following cranial cruciate ligament surgery. “We believe veterinarians are in need …
Aratana Therapeutics secures USDA conditional license for canine osteosarcoma vaccineJanuary 10, 2018Aratana Therapeutics announced that its canine osteosarcoma vaccine, Live Listeria Vector (AT-014), has been granted a conditional license by the USDA Center for Veterinary Biologics for the treatment of dogs diagnosed with osteosarcoma, 1 year of age or older. The vaccine is a novel immunotherapy developed by using a listeria-based antigen delivery system licensed from Advaxis Inc. “Osteosarcoma is the most common primary bone tumor in dogs and, …
Aratana secures third FDA approvalAugust 16, 2016The future is much brighter at Aratana Therapeutics Inc. The Leawood, Kan., company this week won U.S. government approval of its third veterinary biopharmaceutical, Nocita (bupivacaine liposome injectable suspension).
FDA approves Aratana’s hunger stimulantMay 18, 2016Good things come to those dogs who wait. Aratana Therapeutics Inc. has quickly earned its second approval of the year from the U.S. Food and Drug Administration.
